Literature DB >> 8021436

The optimal dosing regimen for citalopram--a meta-analysis of nine placebo-controlled studies.

S A Montgomery1, V Pedersen, P Tanghøj, C Rasmussen, P Rioux.   

Abstract

Optimal dosing schedules for an antidepressant drug can only be established during clinical studies in depressed patients. The benefits of antidepressant therapy are usually progressive, and thus patients must be maintained on a particular treatment for at least 3-4 weeks to assess the efficacy of different doses. Meta-analysis, a widely accepted statistical technique which allows the combination of the results of multiple studies, was used to assess the efficacy of several doses of citalopram over nine placebo-controlled clinical trials. Statistically significant differences between citalopram and placebo were found at both the 20 and 40 mg dose levels. The minimal effective dose of citalopram was shown to be 20 mg. However, analysis of patient subgroups revealed a tendency for those patients suffering from severe or recurrent depression to achieve better results with a higher dosage (40 mg), while patients experiencing their first period of depression or with less severe depression responded well to the minimally effective dose of 20 mg.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8021436     DOI: 10.1097/00004850-199403001-00006

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  9 in total

Review 1.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 2.  Selective serotonin reuptake inhibitors in older patients. A tolerability perspective.

Authors:  U Skerritt; R Evans; S A Montgomery
Journal:  Drugs Aging       Date:  1997-03       Impact factor: 3.923

3.  An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women.

Authors:  Brent M Kious; Hana Sabic; Young-Hoon Sung; Douglas G Kondo; Perry Renshaw
Journal:  J Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.153

4.  beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo.

Authors:  W Pirker; S Asenbaum; S Kasper; H Walter; P Angelberger; G Koch; A Pozzera; L Deecke; I Podreka; T Brücke
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 5.  Citalopram--a review of pharmacological and clinical effects.

Authors:  K Bezchlibnyk-Butler; I Aleksic; S H Kennedy
Journal:  J Psychiatry Neurosci       Date:  2000-05       Impact factor: 6.186

6.  Use of the selective serotonin reuptake inhibitor citalopram in treatment of trichotillomania.

Authors:  D J Stein; C Bouwer; C M Maud
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 7.  Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review.

Authors:  Mazda Adli; Christopher Baethge; Andreas Heinz; Nicolas Langlitz; Michael Bauer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04-29       Impact factor: 5.760

8.  Dose-response relationship of recent antidepressants in the short-term treatment of depression.

Authors:  Patricia Berney
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

9.  Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials.

Authors:  Alex Apler
Journal:  BMJ Open       Date:  2011-01-01       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.